However, ACE2 acts as a receptor for SARS-CoV-2, suggesting that inhibition of miR-122 may inhibit the progression of cardiac fibrosis, attenuate the inflammatory response, and prevent the development of HF in COVID-19 patients. This evidence concerns the gene ACE2 and COVID-19.